阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习

Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has gr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
病例报道
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503986/
https://www.ncbi.nlm.nih.gov/pubmed/34521190
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.34
_version_ 1784581238812573696
collection PubMed
description Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
format Online
Article
Text
id pubmed-8503986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-85039862021-10-22 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习 Zhongguo Fei Ai Za Zhi 病例报道 Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed. 中国肺癌杂志编辑部 2021-09-20 /pmc/articles/PMC8503986/ /pubmed/34521190 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.34 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 病例报道
阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title_full 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title_fullStr 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title_full_unstemmed 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title_short 阿来替尼治疗ALK阳性非小细胞肺癌：1例报告及文献复习
title_sort 阿来替尼治疗alk阳性非小细胞肺癌：1例报告及文献复习
topic 病例报道
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503986/
https://www.ncbi.nlm.nih.gov/pubmed/34521190
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.34
work_keys_str_mv AT āláitìnízhìliáoalkyángxìngfēixiǎoxìbāofèiái1lìbàogàojíwénxiànfùxí
AT āláitìnízhìliáoalkyángxìngfēixiǎoxìbāofèiái1lìbàogàojíwénxiànfùxí

Ejemplares similares